The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: "Moment To Celebrate" As Astra Vaccine Approved In UK

Wed, 30th Dec 2020 08:12

(Alliance News) - AstraZeneca said its Covid-19 vaccine has been approved for emergency supply in the UK, with the first doses being released on Wednesday so that vaccinations may begin early in the New Year.

The FTSE 100 pharmaceutical firm said it aims to supply millions of doses in the first quarter as part of an agreement with the UK government to supply up to 100 million doses in total.

The vaccine, developed together with Oxford University, was authorised by the UK Medicines & Healthcare Products Regulatory Agency, recommending two doses administered with an interval of between four and 12 weeks. Clinical trials showed the vaccine to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose.

"Today is an important day for millions of people in the UK who will get access to this new vaccine. It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit," AstraZeneca Chief Executive Pascal Soriot said on Wednesday.

Added UK Secretary of State for Health & Social Care Matt Hancock: "This is a moment to celebrate British innovation - not only are we responsible for discovering the first treatment to reduce mortality for Covid-19, this vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this awful disease."

The AstraZeneca vaccine is the second to be approved in the UK. The Pfizer/Biontech vaccine was approved earlier in December.

AstraZeneca shares were up 1.5% early Wednesday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.1% at 6,607.56

----------

Hang Seng: up 2.2% at 27,141.97

Nikkei 225: closed down 0.5% at 27,444.17

DJIA: closed down 68.30 points, 0.2%, at 30,335.67

S&P 500: closed down 0.2% at 3,727.04

----------

GBP: up at USD1.3537 (USD1.3509)

EUR: up at USD1.2269 (USD1.2246)

Gold: down at USD1,879.34 per ounce (USD1,882.29)

Oil (Brent): up at USD51.36 a barrel (USD51.16)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Wednesday's Key Economic Events still to come

0930 CET EU EuroCOIN indicator of euro area economic activity

0830 EST US goods trade balance

1000 EST US pending home sales index

1030 EST US EIA weekly petroleum status report

----------

More areas in England will be placed under the country's toughest coronavirus restrictions, Health Secretary Hancock is expected to tell the Commons on Wednesday, PA reports. Pressure mounted on the UK government to act as hospitals across England warned of increasing strains on services due to Covid-19 patient numbers, which have reached their highest levels during the pandemic, while 51,135 further cases and 414 deaths were reported on Tuesday. Local authorities in Essex have declared a "major incident" as the number of coronavirus cases threatens to overwhelm health services in the county. Ambulances were seen queueing outside hospitals including the Royal London Hospital in Whitechapel and Queen's Hospital in Romford, both in east London, and Queen Elizabeth Hospital, Birmingham, on Tuesday, and a junior doctor in the capital said his his hospital was "aggressively overstretched" by Covid-19 patients.

----------

UK Prime Minister Boris Johnson is expected to decide imminently on whether to keep secondary schools shut in order to try to reduce coronavirus transmission. Johnson is set to chair a key meeting on Wednesday looking at delaying the reopening of secondary schools, according to the Daily Telegraph. It comes amid growing concerns from unions and scientists about the spread of the virus following the discovery of its much more transmissible variant. London Mayor Sadiq Khan said he did not want to see schools closed or the education of children disrupted. Labour has called for UK Education Secretary Gavin Williamson to make a statement to MPs on Wednesday on the plan for schools and colleges.

----------

The UK will "open a new chapter in our national story", Johnson has claimed as MPs prepare to vote on his Brexit deal. On Wednesday, Parliament will be recalled to give its ruling on the trade agreement reached more than four years after the In/Out referendum in 2016. The EU (Future Relationship) Bill is expected to clear the Commons with the Conservatives and the majority of Labour MPs set to support it, although the SNP, the DUP, Plaid Cymru, the SDLP, Alliance and the Liberal Democrats have all indicated they will not vote for it.

----------

UK house prices surged in December to post their fastest growth in six years, according to the house price index from mortgage lender Nationwide. House prices jumped 7.3% year-on-year in December, accelerating from rises of 6.5% in November and 5.8% in October to achieve the highest annual growth rate since 2014. Month-on-month, house prices rose 0.8%, a touch slower than the 0.9% growth seen in November. The average UK house price stood at GBP230,920 in December versus GBP229,721 in November. House prices ended the year 5.3% above the level prevailing in March, when the pandemic struck the UK.

----------

BROKER RATING CHANGES

----------

none reported

----------

COMPANIES - FTSE 250

----------

Energean said it has agreed with Kerogen Investments, an affiliate of Kerogen Capital, for the acquisition of Kerogen's 30% shareholding in Energean Israel, which would result in Energean owning 100% of Israel unit share capital. A total consideration of between USD380 million and USD405 million, the Mediterranean-focussed gas exploration and production company said. Energean said the acquisition adds 2P reserves of 29.5 billion cubic metres of gas and 30 million barrels of liquids, representing 219 million barrels of oil equivalent in total, to the company. Taking a 100% interest in Energean Israel will enable Energean to fully control its capital structure, it said, enhancing its ability to maximise total shareholder returns.

----------

COMPANIES - MAIN MARKET AND AIM

----------

Exploration and development company Indus Gas reported a decline in pretax profit for the six months to the end of September to USD20.9 million from USD26.1 million a year earlier, as adjusted revenue declined to USD23.2 million from USD27.7 million. The company said its administrative expenses rose to USD586,360 from USD303,970 year-on-year. "While the pandemic has presented unprecedented operational challenges, the company remains focused on executing our strategy to maximize value for all of our stakeholders," said Chair Peter Cockburn.

----------

Wednesday's Shareholder Meetings

Quiz PLC - AGM

Corcel PLC - AGM

Nu-Oil & Gas PLC - AGM

Plexus Holdings PLC - AGM

Secure Property Development & Investment PLC - AGM

Eco (Atlantic) Oil & Gas Ltd - AGM

Gresham Technologies PLC - GM re incentive plan and remuneration policy

eEnergy Group PLC - AGM

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.